Jeff Aguilar

🇵🇭🇨🇦IM PGY-2 DMC Sinai-Grace | Research @Karmanoscancer. #hematology, #oncology #IMG

[Jeffrey West @mathoncbro]

Artificial intelligence agents in cancer research and oncology
- Truhn 2026, Nature Reviews Cancer

[Jeff Aguilar @jeffMDMBA]

Thrilled to announce our meta-analysis and systematic review on myeloid sarcoma is now published in @Cancers_MDPI !

Check out our clinically relevant results here: https://t.co/yM624ajzN7

#leukemia #myeloidsarcoma #CancerResearch

[Dakshin Padmanabhan @DakshinPadman]

Excited to share our new 📃 on myeloid sarcoma (MS), where we found frequent (56%) NGS discordance between bone marrow and MS tissue and exclusive presence of NPM1 mutations in MS- which should be checked routinely and targeted! @jeffMDMBA @malignantheme

https://t.co/FKcvtIcdOQ

[Jeff Aguilar @jeffMDMBA]

Getting ready for the Ham-Wasserman lecture with the boys and our favourite cells @DakshinPadman @sikchoh #ASH25

[Suresh Balasubramanian @malignantheme]

Congratulations @OpsBug @abdulmoiz82! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models @MDPIOpenAccess @jeffMDMBA @NanjaSushmitha @JulieBoerner2 @CarmeloGurnari @Bahaj_MD @tariqkewan @VisconteValeria

[Jeff Aguilar @jeffMDMBA]

@BloodAdvances @DakshinPadman

[Suresh Balasubramanian @malignantheme]

Excited to share our latest findings! Join us this evening at Poster 2768 as @sandhyadhiman5 presents on menin interaction and nuclear export inhibition in NPM1-mutant AML.#ASH24 @ASH_hematology

[Suresh Balasubramanian @malignantheme]

How do TP53 configurations evolve with treatment and impact prognosis? @DakshinPadman will present intriguing findings tonight. Don’t miss it! #ASH24 @ASH_hematology @waynestate @karmanoscancer @KarmanosHemeOnc @OpsBug @jeffMDMBA

[Jeff Aguilar @jeffMDMBA]

@kim_aldecoa @UCIrvineHealth @THO_WSU_IM Congrats Kim!

[Jeff Aguilar @jeffMDMBA]

Excited to present our poster on mutational site-specificity and concordance/discordance characteristics in myeloid sarcoma here at #ASCO24 !

Big thanks to mentor @malignantheme

cc: @DakshinPadman

@karmanoscancer @IMG_Oncologists #leusm

[Suresh Balasubramanian @malignantheme]

Excited to present our work on Telomere biology gene mutations in MDS and IPSS-M(R) work here! @OpsBug @jeffMDMBA @karmanoscancer

[Jeff Aguilar @jeffMDMBA]

Check out our interesting case report of pancytopenia post mild COVID recovery, featured as the cover story of Hematology Reports Vol. 16, Issue 1 @malignantheme @OpsBug

[Hematology Reports MDPI @HematologyRepo1]

🌟🌟Two cases of new-onset PNH/aplastic anemia syndrome and aplastic anemia associated with COVID-19, but but the exact mechanism is still unknown.
🔗https://t.co/m7sf8LK7U8
👨‍🔬 By Dr. Suresh Balasubramanian
@MDPIOpenAccess

[Carmelo Gurnari @CarmeloGurnari]

What a wonderful story put together by Dr.Kubota! Congrats to Dr. Maciejewski’s Lab ⁦@ClevelandClinic⁩ Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting | ⁦@NatureComms⁩ https://t.co/4X0JWR7uMC

[Jeff Aguilar @jeffMDMBA]

“If you're not using it, you're like those kids who are coming out of college in 1990 and still they’re not learning how to use word processors.”

[NEJM AI @NEJM_AI]

In a talk @BrownMedicine, Editor-in-Chief @zakkohane, urged doctors-in-training to understand and make use of artificial intelligence.

“It's an existential opportunity and threat to medicine to not take [AI] seriously.”

See what else he said: https://t.co/UHX9pTOnLU

[Jeff Aguilar @jeffMDMBA]

Some key findings for OS based on ELN favourable risk and secondary type mutations on NPM1 mt in De novo and t-AML #ASH23

https://t.co/4p2GI9A4Sn

[Suresh Balasubramanian @malignantheme]

@opsbug discussing now on the impact of NPM1 mutation across denovo and t-AML settings! #ASH23

[Suresh Balasubramanian @malignantheme]

Does NPM1 MT convey similar impact when in De Novo vs T/sAML? 👇✅ your 🗓️ for this session that begins at 245PM today! #ASH23 @OpsBug @jeffMDMBA @NanjaSushmitha @LakshmiBPotluri

[Diego Adrianzen-Herrera, MD, MSc @diegoah66]

#ASH23 News Daily Monday AM edition is out. Our piece ‘It’s time to sp(l)ice things up’ covers fantastic work by @SBenbarche @AbdelWahablab, which was presented at #ASH23 Plenary Session. @ASH_hematology. Read it here: https://t.co/fQr5nVBYy8

@NatashaSzuber @JuliPerezBot

[Jeff Aguilar @jeffMDMBA]

Our #ASH23 poster on meta-analysis of myeloid sarcoma, #3811, in 900s section. One of the largest cohorts of myeloid sarcoma, pooled to gain insights on the disease!

Cc: @DakshinPadman

#ASHKudos to mentor and PI @malignantheme

https://t.co/ZGC4mPwd4S

[Jeff Aguilar @jeffMDMBA]

#ASHKudos to this morning’s presentations in Emerging Tools, Techniques and AI in Hematology. Exciting to learn more about machine learning and computational models under development #ASH23

[Suresh Balasubramanian @malignantheme]

Epigenetic aging and age acceleration can be potential biomarkers for targeted therapy in AML. More interesting data being shared by @OpsBug @jeffMDMBA #ASH23

[Suresh Balasubramanian @malignantheme]

2 oral presentations and 5 posters at ASH 2023 from us! More details after the embargo! Felicitations! @OpsBug @NanjaSushmitha @LBP0818 @jeffMDMBA @DakshinPadman @karmanoscancer